Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

Background: The experience of Kymriah® and Yescarta® provides real-world examples of how health-care systems approach and manage the reimbursement of one-off, high-cost, cell, and gene therapies, and the decision uncertainty and affordability challenges they present. Objective: To provide an overvie...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Jesper, Hanna, Eve, Kefalas, Panos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006635/
https://www.ncbi.nlm.nih.gov/pubmed/32082514
http://dx.doi.org/10.1080/20016689.2020.1715536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006635/
https://www.ncbi.nlm.nih.gov/pubmed/32082514
http://dx.doi.org/10.1080/20016689.2020.1715536

Ejemplares similares